tiprankstipranks
Advertisement
Advertisement

SNGX Stock Latest News

Soligenix reports Q1 EPS (28c) vs. (97c) last year
The FlySoligenix reports Q1 EPS (28c) vs. (97c) last year
13d ago
SNGX
Soligenix price target lowered to $1.50 from $10 at Alliance Global
PremiumThe Fly
Soligenix price target lowered to $1.50 from $10 at Alliance Global
17d ago
SNGX
Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma
PremiumThe Fly
Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma
23d ago
SNGX
Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives
PremiumCompany Announcements
Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives
23d ago
8K
SNGX
Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach 
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach 
30d ago
SNGX
Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
PremiumTipRanks NewswireSoligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
1M ago
SNGX
Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results
1M ago
SNGX
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy 
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy 
2M ago
SNGX
Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial
PremiumThe Fly
Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial
2M ago
SNGX
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
2M ago
SNGX
SNGX Earnings this Week: How Will it Perform?
PremiumPre-Earnings
SNGX Earnings this Week: How Will it Perform?
2M ago
SNGX
Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease
2M ago
SNGX
Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease
PremiumThe FlySoligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease
2M ago
SNGX
Soligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach
2M ago
SNGX
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
2M ago
SNGX
Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
2M ago
SNGX
Soligenix (NASDAQ: SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication
2M ago
SNGX
Soligenix announces HyBryte clinical summary published
PremiumThe Fly
Soligenix announces HyBryte clinical summary published
2M ago
SNGX
Soligenix (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease
2M ago
SNGX
Soligenix says SGX945 granted PIM designation in UK by MHRA
PremiumThe FlySoligenix says SGX945 granted PIM designation in UK by MHRA
2M ago
SNGX
Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach
3M ago
SNGX
Soligenix receives positive opinion from EMA for OOD request for dusquetide
Premium
The Fly
Soligenix receives positive opinion from EMA for OOD request for dusquetide
3M ago
SNGX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >